Overview
- The company now expects about $1.9 billion in 2025 revenue, trimmed GAAP operating expenses by an additional $200 million, and projects roughly $8.1 billion in year-end cash.
- CEO Stephane Bancel said 2025 annual operating expenses were reduced by approximately $2 billion, surpassing earlier cost-cutting commitments.
- Guidance reaffirmed up to 10% revenue growth in 2026 with operating expenses targeted at $4.2 billion to $4.6 billion and a break-even objective in 2028.
- Shares rose 12.8% to $38.20 on Tuesday and finished near $39.60, while coverage noted a roughly 30% gain across the first eight trading days of 2026.
- The update came at the J.P. Morgan Healthcare Conference, with reports citing a technical “golden cross” and a breakout above a $36 pivot, and official FY25 results due next month.